The Flow Cytometry Core Facility (FCCF) at the Moffitt Cancer Center was established in 1990 to provide a centralized flow cytometry service for Cancer Center members. Flow cytometry is an indispensable analytical tool for cell biology, immunology and translational research efforts at the Cancer Center. This technology provides a means for rapidly and accurately analyzing multiple characteristics of biological particles, as well as an ability to rapidly isolate and purify cell populations of interest for the purpose of assessing immunological functions and molecular distinctions, cell culture cloning and animal transplantation studies. The FCCF is staffed with highly trained instrument specialists with a combined 36 years of research-based flow cytometry experience. The facility houses six bench-top analyzers, two cell sorters, a bead array analyzer, an automated bead sorter and a fluorescent microscope. This includes the most recently added BD Biosciences customized LSR II analyzer, which was added in response to increased demand for sophisticated polychromatic analyses and high throughput capability. Its customized optical bench has expanded services to the Moffitt investigators doing novel, cutting-edge cancer biology studies. Fifty-six funded members routinely access the FCCF, which is up from thirty-nine in the 2006 review period. In 2008, the FCCF began to use the Laboratory Information Management System (LIMS) to consolidate usage tracking, scheduling, and billing. Flow LIMS also provides a secure repository for Core project data that is accessible by the Pl and the laboratory staff. The FCCF provides critical support for the scientific programs at the Cancer Center by providing investigators with access to state-of-the-art instrumentation, cutting-edge cytometry applications and an exceptionally well trained staff. Overall usage in the FCCF has increased over 30% since the 2006 CCSG submission. The Core requests CCSG Support of $57,049, which is 24% of its operational budget. Over 93% of usage is by Moffitt members and peer-reviewed.
The FCCF provides Moffitt Members a high-quality, state-of-the-art facility that has consistently met investigators'demands for flow cytometry. The core provides researchers with a well-managed, cost-effective facility that functions as a repository for centralized technical expertise, sophisticated instrumentation and software, as well as educational and training opportunities.
|Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y et al. (2016) Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet 25:3600-3612|
|Weber, Jeffrey; Gibney, Geoffrey; Kudchadkar, Ragini et al. (2016) Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res 4:345-53|
|Reed, Damon R; Mascarenhas, Leo; Manning, Kathleen et al. (2016) Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. Cancer Med 5:294-303|
|Turner, Joel G; Dawson, Jana L; Grant, Steven et al. (2016) Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol 9:73|
|Haake, Scott M; Li, Jiannong; Bai, Yun et al. (2016) Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics. Clin Cancer Res :|
|Schabath, Matthew B; Massion, Pierre P; Thompson, Zachary J et al. (2016) Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One 11:e0159880|
|Kim, Jae-Young; Welsh, Eric A; Fang, Bin et al. (2016) Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. Mol Cancer Res 14:1019-1029|
|Extermann, Martine; Leeuwenburgh, Christiaan; Samiian, Laila et al. (2016) Impact of chemotherapy on medium-term physical function and activity of older breast cancer survivors, and associated biomarkers. J Geriatr Oncol :|
|Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2016) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol :|
|Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96|
Showing the most recent 10 out of 974 publications